HC Wainwright Issues Pessimistic Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price

BiomX (NYSEAMERICAN:PHGE) had its price target lowered by HC Wainwright from $21.00 to $15.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

BiomX Price Performance

PHGE stock opened at $0.56 on Friday. The stock’s 50-day moving average is $0.57. The company has a market cap of $10.25 million, a P/E ratio of -0.18 and a beta of 1.27. BiomX has a 52 week low of $0.48 and a 52 week high of $4.90.

BiomX Company Profile

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).